ECP may be effective in treating Crohn's disease

May 25, 2007

(Washington, DC - May 23, 2007) -- Results from an international multi-center Phase II clinical trial suggest that extracorporeal photopheresis (ECP) may be effective in treating patients with clinically active (OR symptomatic) Crohn’s disease who cannot tolerate or are refractory to immunosuppressants and/or anti-TNF agents. A 50% response rate after 3 months of ECP treatment was noted in the study, using standard disease activity criteria, as presented this afternoon at a scientific research session of Digestive Disease Week (DDW). The majority of patients who responded to ECP therapy had a notable improvement in their disease symptoms and signs after only six weeks of treatment.

"We show in this pilot study that ECP is effective in patients with Crohn's disease (CD) that have previously failed the strongest therapies we currently have," explains Maria Abreu, MD, Associate Professor in The Henry D. Janowitz Division of Gastroenterology and in the Center for Immunobiology at The Mount Sinai Medical Center. ECP is believed to bolster tolerance in the immune system, which may be important in immune-mediated diseases such as Crohn’s. In contrast, most patients with inflammatory bowel disease are currently treated with medicines that suppress the immune system. Unlike ECP, those medications can have many serious side effects.

The 28 patient trial studied the safety and efficacy of ECP in patients with a Crohn’s Disease Activity Index (CDAI) of at least 220 and less than 450 indicating that at least moderately active symptomatic CD was present. Clinical response was defined as a CDAI decrease of 100 or greater from baseline and/or a CDAI of less than 150 at week 12. Patients received two treatments of ECP weekly from weeks 0-4 and two treatments every other week from weeks 6-12 with no infectious complications reported.

"The findings of our study suggest that Crohn’s disease patients who have not responded to other therapies may benefit from ECP," concludes Dr. Abreu.

Source: The Mount Sinai Hospital / Mount Sinai School of Medicine

Explore further: New support method improves health of kidney disease patients

add to favorites email to friend print save as pdf

Related Stories

Image: Galactic wheel of life shines in infrared

54 minutes ago

It might look like a spoked wheel or even a "Chakram" weapon wielded by warriors like "Xena," from the fictional TV show, but this ringed galaxy is actually a vast place of stellar life. A newly released ...

Sex-loving, meat-eating reptiles have shorter lives

57 minutes ago

The health risks and benefits of vegetarianism have long been discussed in relation to the human diet, but newly published research reveals that it's definitely of benefit to the reptile population. That, ...

Ericsson profit down 10 pct despite higher sales

59 minutes ago

Wireless equipment maker Ericsson says its third-quarter earnings slumped 10 percent despite higher sales due to increased operating costs and negative effects from currency hedging.

Recommended for you

First case of Ebola confirmed in Mali

3 hours ago

Mali's health ministry on Thursday said the country had its first confirmed case of Ebola after a two-year-old girl who had recently been in Guinea tested positive for the virus.

New York confirms first Ebola case

3 hours ago

A doctor who recently returned to New York from treating Ebola patients in Guinea tested positive on Thursday for the deadly virus, the first confirmed case in the city, officials said.

User comments : 0